Drug intelligence / Profile preview

risankizumab

Development stage: Approved
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Risankizumab is a humanized IgG1 monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By inhibiting IL-23, risankizumab reduces inflammation associated with several autoimmune diseases. It is primarily indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Risankizumab was developed by AbbVie and Boehringer Ingelheim.

Brand names: SKYRIZI
Other names: 瑞卡西单抗

Targets

IL23A (Interleukin-23 p19 Subunit)

Beyond the preview

Go deeper on risankizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on risankizumab.

Explore the full profile